Literature DB >> 10913404

Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage.

V M Manikal1, D Landman, G Saurina, E Oydna, H Lal, J Quale.   

Abstract

Acinetobacter species are problematic nosocomial pathogens. In November 1997, pathogens isolated by microbiology laboratories were collected from 15 hospitals in Brooklyn, New York. Acinetobacter species accounted for 10% of gram-negative isolates. Only half of Acinetobacter species were susceptible to carbapenems; 11 hospitals had at least 1 isolate resistant to carbapenems. Other Acinetobacter susceptibility rates were as follows: polymyxin, 99%; amikacin, 87%; ampicillin/sulbactam, 47%; ceftazidime, 25%; and ciprofloxacin 23%. Overall, 10% were resistant to all commonly used antibiotics. Genetic analysis by use of pulsed-field gel electrophoresis of 12 carbapenem-resistant isolates revealed 4 strains that were recovered from >1 hospital, which suggests interinstitutional spread. Antibiotic usage data from 11 hospitals revealed that the use of third-generation cephalosporins was associated significantly with the percentage of carbapenem-resistant strains (P=.03). Resistant Acinetobacter species have become endemic in Brooklyn, New York. Citywide strategies that involve surveillance, infection-control practices, and the reduction of antibiotic usage may be necessary to control the spread of these pathogens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913404     DOI: 10.1086/313902

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  50 in total

1.  Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain.

Authors:  F Lopez-Otsoa; L Gallego; K J Towner; L Tysall; N Woodford; D M Livermore
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Clonal diversity of nosocomial epidemic Acinetobacter baumannii strains isolated in Spain.

Authors:  Pilar Villalón; Sylvia Valdezate; Maria J Medina-Pascual; Virginia Rubio; Ana Vindel; Juan A Saez-Nieto
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

4.  Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii.

Authors:  L A Arroyo; A García-Curiel; M E Pachón-Ibañez; A C Llanos; M Ruiz; J Pachón; J Aznar
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

5.  Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test.

Authors:  F A Haddad; K Van Horn; C Carbonaro; M Aguero-Rosenfeld; G P Wormser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

6.  OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in Acinetobacter baumannii.

Authors:  Laurent Poirel; Sophie Marqué; Claire Héritier; Christine Segonds; Gérard Chabanon; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 7.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

8.  In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.

Authors:  Ellen S Moland; David W Craft; Seong-geun Hong; Soo-young Kim; Lucas Hachmeister; Shimon D Sayed; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

9.  Multidrug-resistant Acinetobacter baumannii in New York City - 10 years into the epidemic.

Authors:  Daniel J Morgan; Scott A Weisenberg; Michael H Augenbraun; David P Calfee; Brian P Currie; E Yoko Furuya; Robert Holzman; Marisa C Montecalvo; Michael Phillips; Bruce Polsky; Kent A Sepkowitz
Journal:  Infect Control Hosp Epidemiol       Date:  2009-02       Impact factor: 3.254

10.  Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance.

Authors:  D W Wareham; D C Bean; P Khanna; E M Hennessy; D Krahe; A Ely; M Millar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-19       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.